ArticleFrontiers in cell and developmental biology2026
Breast cancer bone metastasis and bone metastatic cells retain NKG2DLs intracellularly: could this be a strategy to evade immune recognition?
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone metastases dramatically worsen breast cancer (BC) prognosis reducing overall survival. Natural killer (NK) cells recognize and eliminate malignant cells through the interaction with NKG2D receptor ligands (NKG2DLs) on cancer cells. Tumors often evade NK surveillance by downregulating the NKG2DLs expression and avoid recognition, but whether this occurs in bone metastases remains unclear. This study investigates mechanisms of NKG2DLs downregulation in primary BC and bone metastases (BoMet). Expression and localization of the NKG2D/NKG2DL axis components were investigated in BC tissues (with and without metastases), paired bone metastatic ductal carcinoma (bmDC), BoMet, and in BC cells lines of varying invasiveness. In bmDC and BoMet, major histocompatibility complex class I chain-related protein A and B (MICA/B) and UL16-binding protein 2 (ULBP2) localized in perinuclear area, contrasting with predominantly cytosolic distribution in non-metastatic BC. Similarly, invasive MDA-MB-231 and MDA-BoM-1833 showed NKG2DLs perinuclear localization and co-localization with the Golgi apparatus, while less invasive MCF7 showed a prominent cytosolic distribution. Accumulation of NKG2DLs in membrane and cytoskeletal fractions further supports this pattern. Additionally, when N-glycosilation is impaired, NKG2DLs fail to reach the cell surface in metastatic cell lines, while are still transported through the Golgi apparatus and delivered to the plasma membrane, resulting in increased surface expression irrespective of correct glycosylation. Our findings suggest that invasive and bone-metastatic breast cancer cells are more dependent on correct glycosylation and intracellular trafficking for NKG2DL surface expression than non-metastatic breast cancer cells. This difference may have important implications for potential immune evasion mechanisms and for the development of therapeutic strategies targeting bone metastases in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.